US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Amgen Inc.

AMGNNASDAQ

243.85

USD
-1.32
(-0.54%)
After Hours Market
20.25P/E
12Forward P/E
0.92P/E to S&P500
130.216BMarket CAP
3.17%Div Yield
Upcoming Earnings
7 Feb-11 Feb
Shares Short
1/13/23
8.78M
Short % of Float
1.65%
Short % of Shares Outs.
1.64%
% Held by Insiders
0.21%
% Held by Institutions
80.43%
Beta
0.66
PEG Ratio
2.65
52w. high/low
296.67/214.39
Avg. Daily Volume
2.75M
Return %
Stock
S&P 500
1 year
10.01
(7.99)
3 years
5.85
23.80
5 years
39.17
56.27
Scale: |
High
Low
66.51
39.16
64.76
44.96
61.26
50.26
65.00
47.66
90.81
63.30
119.70
81.56
173.14
108.20
181.81
130.09
176.85
133.64
191.10
147.12
210.19
163.31
244.99
166.30
264.97
177.05
276.69
198.64
296.67
214.39
276.84
236.37
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
13.22
14.02
14.41
15.68
17.22
22.28
24.80
26.43
28.58
30.74
31.26
35.93
38.61
43.39
44.33
48.93
Earnings per share
2.83
3.92
4.53
4.82
4.07
5.61
6.75
6.80
9.15
10.32
2.71
12.70
12.96
12.40
10.06
12.18
FCF per share
3.70
4.97
5.71
5.42
5.03
6.70
7.43
9.95
11.12
12.72
14.38
15.97
14.10
16.88
14.30
16.33
Dividends per share
- -
- -
- -
- -
0.55
1.44
1.88
2.44
3.16
4.01
4.60
5.31
5.80
6.41
6.85
- -
CAPEX per share
1.13
0.63
0.52
0.60
0.63
0.89
0.92
1.32
0.86
1.12
0.91
1.12
1.02
1.04
1.50
1.74
Book Value per sh.
16.00
19.05
22.31
24.94
21.03
24.59
29.34
33.96
37.05
39.94
34.53
18.91
15.99
16.06
11.43
6.80
Comm.Shares outs.
1,117
1,070
1,016
960
905
775
753
759
758
748
731
661
605
586
586
538
Avg. annual P/E ratio
20.5
13.0
12.1
11.5
13.7
13.6
15.4
19.4
17.2
15.0
62.9
14.8
15.1
18.5
23.1
20.2
P/E to S&P500
1.2
0.6
0.2
0.6
0.8
0.9
0.9
1.1
0.9
0.7
2.7
0.6
0.6
0.5
0.8
1.0
Avg. annual div. yield
- -
- -
- -
- -
1.0%
1.9%
1.8%
1.9%
2.0%
2.6%
2.7%
2.8%
3.0%
2.8%
3.0%
- -
Revenue (m)
14,771
15,003
14,642
15,053
15,582
17,265
18,676
20,063
21,662
22,991
22,849
23,747
23,362
25,424
25,979
26,323
Operating margin
26.9%
34.8%
37.6%
36.8%
27.7%
32.3%
31.4%
30.9%
39.1%
42.6%
43.6%
43.2%
41.4%
35.9%
29.4%
36.3%
Depreciation (m)
1,202
1,073
1,049
1,017
1,060
1,088
1,286
2,092
2,108
2,105
1,955
1,946
2,206
3,601
3,398
- -
Net profit (m)
3,166
4,196
4,605
4,627
3,683
4,345
5,081
5,158
6,939
7,722
1,979
8,394
7,842
7,264
5,893
6,552
Income tax rate
20.1%
20.1%
11.5%
13.0%
11.3%
13.3%
3.5%
7.6%
13.0%
15.7%
79.4%
12.1%
14.2%
10.7%
12.1%
10.8%
Net profit margin
21.4%
28.0%
31.5%
30.7%
23.6%
25.2%
27.2%
25.7%
32.0%
33.6%
8.7%
35.3%
33.6%
28.6%
22.7%
24.9%
Working capital (m)
6,862
10,335
15,059
16,559
21,839
23,018
19,420
27,705
29,851
34,806
40,456
24,130
5,605
9,491
7,201
6,499
Long-term debt (m)
9,177
9,176
10,601
10,874
21,344
24,034
29,623
30,215
29,306
30,193
34,190
29,510
26,950
32,895
33,222
37,354
Equity (m)
17,869
20,386
22,667
23,944
19,029
19,060
22,096
25,778
28,083
29,875
25,241
12,500
9,673
9,409
6,700
3,661
ROIC
11.1%
13.3%
14.3%
14.0%
9.8%
11.4%
10.4%
9.9%
12.5%
13.2%
3.2%
18.2%
19.1%
16.4%
14.2%
17.3%
Return on capital
11.4%
14.4%
14.6%
13.6%
9.7%
11.2%
9.5%
9.6%
12.7%
13.4%
13.6%
16.5%
17.5%
14.9%
12.9%
14.7%
Return on equity
17.7%
20.6%
20.3%
19.3%
19.4%
22.8%
23.0%
20.0%
24.7%
25.8%
7.8%
67.2%
81.1%
77.2%
88.0%
179.0%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
86.4%
74.3%
72.2%
64.1%
65.5%
61.2%
(70.0)%
58.2%
55.3%
48.3%
31.9%
- -
Div.&Repurch./FCF
116.7%
39.7%
52.3%
71.2%
193.7%
85.4%
34.9%
23.9%
49.6%
62.1%
62.1%
201.8%
131.4%
73.2%
107.2%
- -
Capital Structure
31 Dec · 2022 | Q4
All numbers in millions
Total liabilities
$ 61,460
Total assets
$ 65,121
Long-term debt
$ 37,354
Cash and equiv.
$ - -
Goodwill
$ 15,529
Retained earnings
$ (18,048)
Common stock
535
Enterprise Value
$ 167,570
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
10,647
8,037
- -
Receivables
4,525
4,895
5,563
Inventory
3,893
4,086
4,930
Other
2,079
4,090
5,427
Current assets
21,144
19,385
22,186
Acc. Payable
1,421
1,366
- -
Debt due
91
87
1,591
Other
10,141
10,731
14,096
Current liabilities
11,653
12,184
15,687
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
1.32%
2.68%
3.95%
Cash flow
4.82%
(3.43)%
6.29%
Earnings
11.18%
(5.41)%
30.61%
Dividends
- -
- -
- -
Book value
(45.36)%
(24.87)%
(14.83)%
Insider Trading
Type
Shares
Date
Khosla Rachna
Sale
387
11/09/22
Kullman Ellen Jamison
Award
222
11/08/22
Drake Michael V
Award
171
11/08/22
Ishrak Omar
Award
222
11/08/22
Grygiel Nancy A.
Sale
545
11/08/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
6,161
6,206
6,423
6,634
25,424
2021
5,901
6,526
6,706
6,846
25,979
2022
6,238
6,594
6,652
6,839
26,323
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
3.11
3.08
3.45
2.76
12.40
2021
2.81
0.79
3.22
3.24
10.06
2022
2.74
2.45
3.98
3.00
12.18
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.61
1.61
1.60
1.59
6.41
2021
1.73
1.72
1.70
1.69
6.85
2022
2.01
1.93
1.93
- -
5.87
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. Robert Bradway
Full-time employees:
24,200
City:
Thousand Oaks
Address:
1 Amgen Center Dr
IPO:
May 1, 1987
Website:
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Recent News
· 31 Jan, 2023 · The Wall Street Journal
· 12 Dec, 2022 · The Wall Street Journal
· 12 Dec, 2022 · The Wall Street Journal
· 12 Dec, 2022 · The Wall Street Journal
· 12 Sep, 2022 · The Wall Street Journal
· 4 Aug, 2022 · The Wall Street Journal
· 1 Aug, 2022 · The Wall Street Journal
· 26 Jul, 2022 · The Wall Street Journal
· 3 Aug, 2021 · The Wall Street Journal
· 28 May, 2021 · The Wall Street Journal